Abstract：【Objective】To investigate drug resistance monitoring in 72 cases of pulmonary tuberculosis complicated with lung cancer in our hospital. 【Methods】Seventy-two patients with pulmonary tuberculosis complicated with lung cancer were included in the pulmonary tuberculosis with lung cancer group. Another 94 patients with simple pulmonary tuberculosis admitted in the same period were included in the pulmonary tuberculosis group. The drug resistances of Mycobacterium tuberculosis to isoniazid (INH), rifampicin (RFP), streptomycin (SM) and ethambutol (EMB) were analyzed. 【Results】The acquired drug resistance rate of pulmonary tuberculosis with lung cancer group (89.47%) was significantly higher than that of the pulmonary tuberculosis group (P<0.05). The probabilities of resistance to RFP and EMB in the pulmonary tuberculosis with lung cancer group were significantly higher than that in the pulmonary tuberculosis group (P<0.05). The probability of multi-drug resistance in the pulmonary tuberculosis with lung cancer group (71.93%) was significantly higher than that in the pulmonary tuberculosis group (39.04%) (P<0.05). 【Conclusion】Compared to simple pulmonary tuberculosis, the acquired drug resistance rate, multi-drug resistance rate, and frequency of resistance to RFB and EMB of pulmonary tuberculosis with lung cancer are higher.
韩娜;赵磊;王丽;田彦卿. 肺结核合并肺癌患者的结核分枝杆菌耐药性分析[J]. 医学临床研究, 2016, 33(10): 1883-1885.
HAN Na, ZHAO Lei, WANG Li, et al. Drug Resistance Monitoring Analysis of Pulmonary Tuberculosis Complicated with Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2016, 33(10): 1883-1885.
2016, Vol. 33 
